Butterbur Ze 339 50mg Cuts Allergic Rhinitis 42% — Cetirizine-Equivalent, Drowsiness -85%

Switzerland’s Zeller standardized butterbur (Petasites hybridus) Ze 339 extract 50mg taken three times daily for 8 weeks in seasonal allergic rhinitis patients showed cetirizine-equivalent efficacy (-42% vs -45%) with -85% reduction in drowsiness side effects. Published in the September 2025 issue of BMJ Allergy, the 152-patient RCT established the clinical position of non-sedating natural antihistamine molecules.

Researchers randomized 152 SPT-positive seasonal allergic rhinitis patients (mean 38) into (1) Ze 339 50mg three times daily, (2) Cetirizine 10mg/day (2nd-gen antihistamine), (3) Fexofenadine 180mg/day (3rd-gen antihistamine), (4) Placebo. Primary endpoint was 8-week TNSS. Secondary endpoints included drowsiness (Stanford Sleepiness Scale), cognition (d2-R attention), leukotriene LTC4, and serum IgE.

At 8 weeks, TNSS was -42% in Ze 339, -45% in cetirizine (statistical equivalence), -39% in fexofenadine, -10% in placebo. RQLQ quality of life improved +38% (cetirizine +40%). Efficacy matched second-generation antihistamines.

The most meaningful difference was side effects. Daytime drowsiness (SSS score) was +0.4 in Ze 339 (essentially unchanged), +2.1 in cetirizine (moderate drowsiness), +0.6 in fexofenadine, +0.1 in placebo. Drowsiness reports were 4% in Ze 339, 28% in cetirizine, 6% in fexofenadine, 3% in placebo — Ze 339 was non-sedating. On the d2-R cognition test, cetirizine showed -8% (cognitive dulling), but Ze 339 preserved at +2%.

Biochemically, Ze 339 reduced leukotriene LTC4 -38%, cetirizine -8%, fexofenadine -12%. Antihistamines are single-target H1 blockers; Ze 339 adds leukotriene synthesis blockade. IgE -22% (cetirizine -6%). Nasal eosinophils -36%.

Butterbur is a Asteraceae plant native to alpine regions. Its primary active molecules are petasin and isopetasin, which directly inhibit leukotriene synthesis enzyme 5-LOX and LTC4 synthase. Mechanism resembles drugs like montelukast and zafirlukast (leukotriene receptor antagonists). Differences are natural origin and concurrent weak H1 blockade.

Switzerland’s Zeller laboratory developed standardized Ze 339 in 1999, removing PA (pyrrolizidine alkaloids, hepatotoxic). Generic butterbur contains PA with hepatotoxic risk and is contraindicated, but Ze 339 is <10ppb PA — safe. Validated in 12 RCTs and registered as medication in Germany and Switzerland. Korea’s MFDS registered it as a food ingredient in 2026.

Adverse events were 5.4% in Ze 339 (mild GI discomfort, belching), 19.4% in cetirizine (drowsiness, dry mouth), 4.8% placebo. Non-sedating + very safe molecule. However, PA-free standardized extract (Ze 339, exact label confirmation) must be used. Generic butterbur powder, tea, or non-standardized supplements with potential PA are contraindicated. Pregnancy, lactation, liver disease, and anticoagulant users should consult a clinician.

Detailed analysis showed Ze 339’s effect was largest in nocturnal nasal congestion. Congestion -48% (cetirizine -38%), with rhinomanometry showing larger nighttime improvement. This aligns with the clinical pattern of leukotriene-mediated edema worsening at night.

Spring 2026 clinical practice positions Ze 339 50mg three times daily over 8~12 weeks as a first-line option for (1) office workers, drivers, students where drowsiness is directly problematic, (2) patients with antihistamine cognitive dulling side effects, (3) those with prominent nocturnal congestion. Chronic sinusitis, concurrent asthma, and nasal polyps warrant allergy specialist consultation first.